Brain Metastases Gene Testing


Crossing The Barrier To Determine Your Options-Precision Treatment Guidance For Patients With Brain Metastases

Metastatic tumours to the brain affect nearly one in four patients diagnosed with cancer, with the highest frequencies of brain metastases observed in patients with lung cancer(35–50%), breast cancer (10–20%), and melanoma (8–10%) . The outcome for patients diagnosed with these tumourshas been very poor, with a typically low survival rate. Brain metastases are usually treated with surgery, radiation, and chemotherapy – eitheras a separate modality or in various combinations. Importantly, increasing evidence has shown that the status of genomic alterations has opened up the possibility for the treatment of brain metastases with targeted therapies.

Clinical Use of Cerebrospinal Fluid Genomic Analysis

Owing to the blood–brain barrier (BBB), only a limited amount of ctDNA from the central nervous system (CNS) can be released to plasma and suggesting plasma-based liquid biopsy might provide incomplete information of brain metastases. Numerous studies have shown that a liquid biopsy using cerebrospinal fluid (CSF) is more sensitive than plasma for detecting  targetable genomic alterations, characterize resistance mechanisms,  and monitoring treatment response in the brain metastasis. Specifically, a non-small cell lung cancer (NSCLC) cohort study showed that in patients with brain metastases, actionable genomic alterations could be found in the CSF of all patients. However, 26.9% of the patients exhibited no genomic changes in the plasma. Therefore, the use of CSF analysis may be more beneficial for a patient with brain metastases.

Image title

Hallmark of ACTCerebra 

  1. For All Solid Tumors

    Select suitable treatment for brain metastases patients based on actionable genetic mutations
  2. Precise Report Content

    Targeted therapies approved by U.S. FDA or in the global clinical trials

Summary of ACTCerebra 

  1. Drug Targeted-Based Panel

     Sequencing of 40 actionable genes.  
  2. Offering Tailored Drug Options

     Analysis of single nucleotide variation (SNV), and small insertion/deletions (InDels) to provide tailored drug options.
  3. Short Turnaround Time

     Providing professional solutions within 9 working days  (starting from the day qualified specimen is received at lab)
  4.  Providing Report Consultation

     Every report is complemented by a consultation with our medical team.
  5.  Pioneering Bioinformatics

     Integration of cancer biology, medical informatics, molecularbiology, cell biology, immunology, bioinformatics, data scienceand pharmaceutical biology to   provide insightful interpretation.
  6.  High Sensitivity

     Next-generation sequencing is used for microscale specimens.

Technical Specification

Sample Types

Cerebrospinal fluid (CSF), 4–8 mL

Next-generation Sequencing

Mutational analysis of 40 actionable genes



   Sequencing Mean Depth

   >800 X